Journal

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease

Read time: 1 mins

Published:9th Oct 2020

Author: Natale P, Palmer SC, Tong A, Ruospo M, Hodson EM, Cooper TE, et al.

Source: Cochrane Database of Systematic Reviews

Availability: Free full text

Ref.:Cochrane Database Syst Rev. 2020;2020(10):CD013751.

DOI:10.1002/14651858.CD013751

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

This review aims to assess the benefits and harms of HIF stabilisers for the treatment of anaemia in people with CKD.

Why it is important to do this review
Evidence for HIF stabilisers to treat anaemia in people with CKD is emerging in RCTs. With data being presented from phase 2 studies for competitive HIF stabilisers and preliminary data from phase 3 study on roxadustat in patients requiring dialysis, sufficient evidence might be available to determine the efficacy and safety of HIF stabilisers compared to other treatment strategies, including ESAs therapy. The effect on metabolic processes, need for iron supplementation, and reassessment of iron parameters might be evaluated. This Cochrane review will evaluate the benefits and potential harms of HIF stabilisers in the setting of CKD and provide a summary of the certainty of available evidence for decision makers including clinicians, patients, and policy‐makers.

Access full article